TABLE 1.
Comparison CD14 polymorphisms and “risk” genotypes (CD14-159CC, FcγRIIA-R/R131) between Hong Kong patients with SARS and control group of Hong Kong blood donors
| Factor | No. (%) of:
|
||
|---|---|---|---|
| SARS patients (n = 152)a
|
Blood donors (n = 198) | ||
| Mild | Severe (ICU)c | ||
| Presence of CD14-159 polymorphismb | |||
| CC | 19 (15) | 8 (31) | 39 (20) |
| CT | 67 (53) | 14 (54) | 95 (48) |
| TT | 40 (32) | 4 (15) | 64 (32) |
| Presence of risk genotypes | 30 (24) | 12 (46) | 53 (27) |
| Absence of risk genotypes | 96 (76) | 14 (54) | 145 (73) |
Mild SARS refers to patients who recovered without the need for intensive care or ventilation.
The difference in linear tread distribution of CD14-159 genotypes (CC, CT, and TT) between the ICU and mild SARS groups was significant (two-by-three contingency table; P = 0.027).
In comparison with the mild SARS group and controls, the incidence of patients carrying risk genotypes in the severe SARS (ICU) group is significantly higher (two-by-two contingency table; for mild SARS, two-sided P = 0.029; odds ratio, 2.74 [1.15 to 6.57]; for controls, P = 0.04; odds ratio, 2.41 [1.05 to 5.54] for controls.